Capricor Therapeutics Inc (NASDAQ:CAPR)’s share price hit a new 52-week low on Wednesday . The company traded as low as $0.85 and last traded at $0.90, with a volume of 100 shares. The stock had previously closed at $0.90.
A number of equities analysts have recently weighed in on the company. TheStreet downgraded Capricor Therapeutics from a “c-” rating to a “d+” rating in a research note on Monday. Zacks Investment Research upgraded Capricor Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $5.83.
The company has a market cap of $32.29 million, a P/E ratio of -2.06 and a beta of -2.65.
Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Capricor Therapeutics had a net margin of 111.24% and a negative return on equity of 204.82%. The firm had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.41 million. As a group, research analysts expect that Capricor Therapeutics Inc will post -0.53 earnings per share for the current year.
About Capricor Therapeutics (NASDAQ:CAPR)
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
See Also: Risk Tolerance
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.